Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - July 8, 2025 765 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MIDAS study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Bus Driver Finds Out Teen With Cancer Can’t Afford Prom &... June 19, 2019 Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma March 16, 2026 Darolutamide in Combination with ADT and Docetaxel Increases Overall Survival in... February 27, 2023 Transforming optimism: finding new ways to treat rare cancers January 27, 2021 Load more HOT NEWS Woman Showed Up To Their Wedding And Stole All Their Gifts.... Cancer Survivors Face High Rates of Housing Insecurity Metastatic Breast Cancer: New ESMO Guideline With Evidence-Based Recommendations [ESMO Press... Survival According Circulating Tumour DNA Status in the Study of Adjuvant...
